C&EN1d
FDA approves drug for neurofibromatosis
The US Food and Drug Administration has approved mirdametinib for the treatment of neurofibromatosis type 1 (NF1) in adults ...
Pharm Exec1d
FDA Approves Pfizer’s Adcetris for Relapsed or Refractory Large B-Cell Lymphoma
Approval of Adcetris provides a new treatment option for patients with relapsed or refractory large b-cell lymphoma who are ...
FiercePharma1d
With new FDA approval, GSK joins Pfizer in the 5-in-1 meningococcal vaccine ring
Pfizer’s two-year run with the only 5-in-1 meningococcal vaccine on the U.S. market has come to an end. Now, GSK is ready to ...
PMLiVE2d
Pfizer granted FDA approval for Adcetris combination in large B-cell lymphoma
Pfizer’s Takeda-partnered blood cancer drug Adcetris (brentuximab vedotin) has been approved by the US Food and Drug ...
BioSpace2d
Pfizer Continues Cancer Rally as Adectris Label Expands to Non-Hodgkin Lymphomas
Leaked data showed that Pfizer’s mevrometostat has strong therapeutic potential in metastatic castration-resistant prostate ...
Hosted on MSN1d
Pharma Stock Roundup: NVS, ABBV M&A Deals, FDA Nod to RHHBY, PFE Drugs
Novartis NVS and AbbVie ABBV announced small M&A deals. The FDA approved the expanded use of Pfizer’s PFE cancer drug ...
US FDA approves GSK's combo meningococcal vaccine
The U.S. Food and Drug Administration approved British drugmaker GSK's combination vaccine to protect against meningococcal ...
FiercePharma2d
Pfizer outlines Talzenna's survival benefit in bid for broad prostate cancer approval
Pfizer hopes a unique life-extension benefit for its Talzenna can serve to further expand the drug’s already ...
BioSpace4d
Leaked Conference Article Shows Pfizer’s Positive Phase I Prostate Cancer Data
A paper inadvertently published on the website of an ASCO conference revealed good results for mevrometostat in treating ...
Pfizer’s Adcetris combination regimen approved by FDA for r/r DLBCL
Pfizer (PFE) announced that the U.S. FDA has approved the supplemental Biologics License Application for ADCETRIS in combination with ...
Pfizer drug acquired in $11B buyout confirms benefit in colon cancer
The results could sway U.S. regulators to convert Braftovi’s accelerated clearance in colorectal tumors into a full approval ...
Morningstar3d
U.S. FDA Approves Pfizer’s ADCETRIS® Combination Regimen for the treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Milestone represents the eighth FDA-approved indication for ADCETRIS, reinforcing its use as a standard of care for certain lymphomas Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and ...